Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03511638 · ClinicalTrials.gov registry record · NA

Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)

A NA study, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
NA
Development phase
372
Enrollment target

NCT03511638 is a NA study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 372 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03511638, a NA study, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
NA
Development phase
372 participants
Enrollment target

Study Summary

A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD

Interventions

  • DEVICE Bausch & Lomb DVisc40
  • DEVICE Alcon VISCOAT®

Trial Details

FieldValue
Enrollment Target 372 participants
Start Date 2018-05-09
Est. Completion 2019-04-01
Phase NA

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT03511638

The ClinicalTrials.gov registry entry for NCT03511638 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Bausch & Lomb DVisc40 is the first listed.

NCT03511638 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03511638 about?

NCT03511638 is a clinical study titled "Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)". A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD

What is the current status of trial NCT03511638?

This trial is currently completed. It is a NA study. The enrollment target is 372 participants. The study started on 2018-05-09. Estimated completion is 2019-04-01.

What interventions are being tested in trial NCT03511638?

The interventions under investigation include: Bausch & Lomb DVisc40 (DEVICE), Alcon VISCOAT® (DEVICE).

Who is sponsoring clinical trial NCT03511638?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.